IMPEDIMED LIMITED — Call Transcript 2023

Sep 10, 2023

==> picture [230 x 54] intentionally omitted <==

11 September 2023

ASX ANNOUNCEMENT

Shareholder Conference Call

ImpediMed Limited (ASX.IPD) today announces that its Directors will host a shareholder conference call at 9:30am AEST (Sydney/Melbourne) on Wednesday, 13 September 2023.

The live call will be hosted by ImpediMed’s chair, Don Williams, who will be joined by the Board of Directors, as well as Managing Director and CEO, Rick Valencia.

To register for the conference call please follow this link:

https://us02web.zoom.us/webinar/register/WN_7E4HFCOaRvCO6CY0xHmHPQ

The Directors will be addressing questions on the call although shareholders are encouraged to send questions in advance to investorrelations@impedimed.com.

Approved for release by the Managing Director & CEO, Richard Valencia.

Contact Details

Investor Relations Contact:	Shareholder Services for voting and proxies:
Hannah Howlett	Orient Capital
WE Communications	T: 1300 859 277
T: +61 450 648 064
E: hhowlett@we-worldwide.com	Link Market Services
E: investorrelations@impedimed.com	T: +61 1300 554 474 E: registrars@linkmarketservices.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDAcleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen atrisk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®] , ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancerrelated lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.

For more information, visit www.impedimed.com.

==> picture [230 x 54] intentionally omitted <==

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.